Autophagy Contribution to Cancer Therapy Resistance
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Autophagy".
Deadline for manuscript submissions: closed (15 July 2024) | Viewed by 1613
Special Issue Editors
Interests: autophagy; signaling; metabolism; acute myeloid leukemia
Special Issues, Collections and Topics in MDPI journals
Interests: host autophagy; metabolism; immune response; acute myeloid leukemia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Unfortunately, for many types of cancer, therapy resistance is common and accounts for most cases of treatment failure. Therefore, the identification of new targets and resistance mechanisms is urgently needed to improve clinical outcomes. The well-conserved catabolic process, autophagy, has previously been implicated in the initiation, progression, and therapeutic resistance of numerous tumors. This survival mechanism, characterized by the lysosomal degradation of cytoplasmic content and damaged organelles, ensures energy and cellular homeostasis. In addition, especially through its role in metabolism regulation, tumor and microenvironmental autophagy have been increasingly associated with oncogenesis. However, studies to better understand its role and identify through which molecular and cellular mechanisms autophagy regulates response to therapy, especially in vivo, are still necessary.
This Special Issue will investigate, in vitro and in vivo, the contribution of autophagy to cancer resistance and relapse, depending on tumor type and the treatments used, in order to understand whether autophagy modulation could be an interesting strategy to improve therapy efficacy.
Dr. Carine Joffre
Dr. Laura Poillet
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- autophagy
- cancers
- therapy resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
